Craftport Cannabis Past Earnings Performance
Past criteria checks 0/6
Craftport Cannabis's earnings have been declining at an average annual rate of -18.4%, while the Pharmaceuticals industry saw earnings growing at 27.3% annually. Revenues have been growing at an average rate of 49.5% per year.
Key information
-18.4%
Earnings growth rate
8.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 23.1% |
| Revenue growth rate | 49.5% |
| Return on equity | n/a |
| Net Margin | -4,454.1% |
| Last Earnings Update | 30 Sep 2022 |
Revenue & Expenses BreakdownBeta
How Craftport Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 22 | 0 | -8 | 3 | 0 |
| 30 Jun 22 | 0 | -8 | 3 | 0 |
| 31 Mar 22 | 1 | -10 | 3 | 0 |
| 31 Dec 21 | 1 | -10 | 3 | 0 |
| 30 Sep 21 | 1 | -13 | 3 | 0 |
| 30 Jun 21 | 1 | -12 | 3 | 0 |
| 31 Mar 21 | 1 | -10 | 3 | 0 |
| 31 Dec 20 | 1 | -10 | 3 | 0 |
| 30 Sep 20 | 1 | -1 | 4 | 0 |
| 30 Jun 20 | 0 | -3 | 4 | 0 |
| 31 Mar 20 | 0 | -3 | 5 | 0 |
| 31 Dec 19 | 0 | -4 | 5 | 0 |
| 30 Sep 19 | 0 | -6 | 6 | 0 |
| 30 Jun 19 | 0 | -6 | 6 | 0 |
| 31 Mar 19 | 0 | -6 | 6 | 0 |
| 31 Dec 18 | 0 | -6 | 6 | 0 |
| 30 Sep 18 | 0 | -8 | 5 | 0 |
| 30 Jun 18 | 0 | -7 | 4 | 0 |
| 31 Mar 18 | 0 | -5 | 3 | 0 |
| 31 Dec 17 | 0 | -4 | 2 | 0 |
| 30 Sep 17 | 0 | -2 | 1 | 0 |
| 30 Jun 17 | 0 | -1 | 1 | 0 |
| 31 Mar 17 | 0 | -1 | 1 | 0 |
| 31 Dec 16 | 0 | -1 | 1 | 0 |
Quality Earnings: CFT is currently unprofitable.
Growing Profit Margin: CFT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CFT is unprofitable, and losses have increased over the past 5 years at a rate of 18.4% per year.
Accelerating Growth: Unable to compare CFT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CFT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (109.7%).
Return on Equity
High ROE: CFT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.